Furthermore, FGFR3 mutations are extremely common in the most benign bladder lesions (low malignant potential neoplasms and urothelial papillomas) and low-grade and -stage tumours (PUNLMP; TaG1), reaching frequencies over 80% in these subgroups [27, 28, 39]. Here, FGFR3 is linked to neoplasm.